Summary & Overview
HCPCS Q5141: Adalimumab-aaty Biosimilar Injection, 1 mg
HCPCS Level II code Q5141 identifies a 1 mg unit of adalimumab-aaty, a biosimilar therapeutic biologic administered by injection. This code matters nationally because biosimilar versions of high-cost biologics influence payer coverage policies, utilization management, and overall drug spending across outpatient and infusion settings. Providers and payers use unit-level HCPCS codes like Q5141 to report administered doses, support billing for drug acquisition and administration, and enable tracking of biosimilar uptake.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will gain a concise overview of the code’s clinical role and typical sites of service, along with the types of benchmarks and policy areas commonly associated with biosimilar injectable agents—coverage criteria, unit-based billing practices, and implications for outpatient administration workflows. The summary highlights where data was not provided in the input and flags that detailed payer-specific coverage rules, reimbursement rates, and associated diagnosis coding are not included here. The content is intended for a national audience of payers, provider billing teams, and policy analysts seeking a clear reference for HCPCS Level II code Q5141 and its role in biosimilar biologic billing.
Billing Code Overview
HCPCS Level II code Q5141 describes an injection of adalimumab-aaty, a biosimilar formulation, billed per 1 mg. The service type is therapeutic biologic injection used for indications where adalimumab products are clinically appropriate. The typical site of service is outpatient infusion/administration settings, including physician offices, outpatient infusion clinics, and hospital outpatient departments where biologic injections are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with established rheumatoid arthritis presents to an outpatient infusion and injection clinic for their maintenance biologic therapy. The patient has been switched to a biosimilar formulation of adalimumab and receives a clinic-administered subcutaneous injection billed as Q5141 (injection, adalimumab-aaty, biosimilar, 1 mg). The clinical workflow includes confirmation of identity and informed consent, review of prior dosing and concurrent medications, screening for active infections or contraindications, preparation of the biosimilar syringe or pen by a licensed nurse, administration of the subcutaneous injection into the abdomen or thigh, observation for immediate adverse reaction for 15–30 minutes, documentation of lot number and expiration, and post‑procedure instructions. Typical sites of service are outpatient clinic, physician office, or ambulatory infusion center. The typical patient scenario includes ongoing monitoring of disease activity, documentation of therapeutic response and adverse events, and coordination with the prescribing rheumatologist for future dosing and supplies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default billing | Use when no special circumstances apply. |